Core Viewpoint - The legal opinion letter confirms that the actual controller of Puris (Shanghai) Pharmaceutical Technology Development Co., Ltd., Lai Chunbao, has the legal qualifications to increase his shareholding in the company, and the increase complies with relevant laws and regulations [1][4][7] Group 1: Shareholding Situation - Before the increase, Lai Chunbao directly held 4,648,150 shares, accounting for 5.85% of the total share capital, while entities controlled by him held an additional 21,171,033 shares, representing 26.63% [4] - Lai Chunbao and his concerted actors collectively held 31,746,533 shares, which is 39.93% of the total share capital [4][7] Group 2: Increase Plan - The increase plan was announced on January 14, 2025, with a commitment to purchase shares worth no less than RMB 6 million and no more than RMB 9 million from January 15, 2025, to July 14, 2025 [5] - The actual increase involved the purchase of 224,800 shares, representing 0.28% of the total share capital, with a total expenditure of RMB 6,742,476.00 (excluding transaction fees) [5][6] Group 3: Information Disclosure - The company has fulfilled its information disclosure obligations regarding the increase, including announcements about the increase plan and its implementation [6][7] - A formal announcement regarding the completion of the increase is expected to be disclosed by June 10, 2025 [6] Group 4: Exemption from Tender Offer - The increase qualifies for exemption from the tender offer requirement as the total shareholding exceeded 30% prior to the increase, and the additional shares acquired did not exceed 2% of the total share capital [7]
普蕊斯: 北京国枫律师事务所关于普蕊斯（上海）医药科技开发股份有限公司实际控制人增持公司股份的法律意见书